80 results about "Metalloprotein" patented technology

The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use. The preparations are novel wide-spectrum antibiotics which have antiviral, antiproliferative, antineoplastic, antiangiogenic, antibacterial, antiparasitic, antiinfective, and anti-inflammatory effects and can be used in the treatment and prevention of diseases such as AIDS, cancers, untoward angiogenesis, pulmonary anthrax, malaria, inflammatory responses, Alzheimer's disease and other diseases.

The invention relates to application of collagen chelate in the preparation of medicament or food for enhancing bone quality. The medicament or food can enhance bone strength, can enhance bone strength and bone density at the same time and can be used for curing and/or preventing osteoporosis. The collagen chelate is a metalloprotein conjugate; compared with calcium carbonate (CaCO3) with the same calcium concentration, the collagen chelate can enhance the bone density by 4.4 percent and enhance the bone strength by 9.9 percent; and compared with a mixture of collagen and calcium carbonate (CaCO3) with the same concentration of collagen and calcium carbonate, the collagen chelate has a more obvious effect.

The present invention relates to high purity ulinastatin and its medicine composition and their preparation process. Specially, the high purity ulinastatin in 50,000 U/ml concentration has optical absorption value at 405 nm not exceeding 0.05 and human urea kininogenase content not exceeding 0.0003 PNAU. The present invention purifies ulinastatin product through adsorption with hydrophobic column, purification in hydrophilic column, combination with metalloprotein in metal chelating column and elution with buffering phosphate solution.

Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the cytoplasmic domain is capable of inhibiting in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.

The present invention relates to assays and kits for detecting or quantifying iron metalloprotein in test samples.

Provided herein, inter alia, are compounds and methods for treating infectious diseases. The compounds provided herein are, inter alia, useful for the treatment of bacterial infections. The compounds provided herein are, inter alia, useful inhibitors of metalloproteins, e.g. UDP-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC).

Compositions and methods for treating, reducing the risk of, or slowing the onset of a neurological disorder or pathological condition in a subject are provided. An inhibitor of the formation of free radical or reactive oxygen species is administered in an effective amount to the subject and the inhibitor prevents tissue and cellular damage and/or necrosis by inhibiting the release of free radicals or reactive oxygen species (ROS) that can cause such damage in the subject. The inhibitor may be a bacterial metalloprotein. An exemplary free radical production inhibitor is the metalloprotein rusticyanin, a type I blue-copper metalloprotein found in the aerobic acidophilic iron-oxidizing bacterium Thiobacillus ferrooxidan. A composition containing the inhibitor of the formation of free radical or reactive oxygen species includes a pharmaceutically acceptable carrier.

The invention discloses a kit for identifying a new coronavirus by applying a mass spectrum system and a use method of the kit. The kit comprises the following components: a U9 buffer solution, a U1 buffer solution and a sodium acetate buffer solution. The using method of the kit comprises the following steps: S1, activating a metalloprotein chip target plate; S2, pretreating a serum sample; S3, extracting protein in the serum sample by using the metalloprotein chip target plate; and S4, acquiring and processing a spectrogram by using an MALDI-TOF mass spectrum system, and analyzing the read spectrogram by using software. Therefore, the kit is high in sensitivity, good in accuracy, simple and convenient to operate, short in consumed time and very suitable for clinical diagnosis.

The present invention provides for spectrometric methods of analyzing plasma or serum for metal distribution in metalloproteins. The methods can be used to assess such conditions as toxicity and disease in subjects.

A method treats and then prevents a virus for afflicting an animal or a human as a metalloprotein mediates the virus. The method administers systemically a therapeutic pharmacological agent of picolinic acid either singly or with interferons, chemokines or cytokines to fight dengue fever virus. The picolinic acid inactivates the metalloprotein that allows replication of the virus. The picolinic acid has the structure of:

where R1, R2, R3, and R4 are mutually exclusive. The viral proteins disintegrate by macrophage proteolytic enzymes stimulated by the picolinic acid.

The invention relates to aryl-sulphonamido compounds endowed with affinity against metallo proteases MMP, having formula (I) below wherein R, R₁, R₂, R₃, G and n have the meanings reported in the specification, properly labelled with diagnostic imaging moieties or even radiotherapeutic moieties. The invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as diagnostic imaging agents or radiotherapeutic agents.

A purified ulinastatin is prepared through adsorbing by hydrophobic column, separating by gel column, combining metalloprotein by metallic chelating column, and eluting with phosphate buffering liquid. A composite medicine containing the purified ulinastatin also disclosed.

The invention discloses a method for separating copper proteome by using copper-chelated magnetic beads, and relates to the technical field of protein chemistry. The method comprises the following steps: taking a biological tissue or cell, after fully grinding with liquid nitrogen, adding protein extracting liquid, and after uniformly mixing, carrying out low-temperature centrifugation, so as to obtain a denatured protein solution; mixing the copper-chelated magnetic beads with the denatured protein solution, and incubating to obtain a magnetic bead protein mixed solution; adding a buffer solution 1 with the volume 1 time of that of the magnetic bead protein mixed solution into the magnetic bead protein mixed solution for suspension, pouring half of the supernate under the external magnetic field, and repeating for 4-5 times to obtain a mixed solution A; adding a buffer solution 2 with the volume 1 time of that of the mixed solution A into the mixed solution A, separating all the specific copper-binding proteins, namely, the copper proteome, and collecting the copper proteome under the external magnetic field. According to the method, the metalloproteome is separated under a denaturing condition by using magnetic bead-IDA, so that the procedures are greatly simplified, and the obtaining efficiency of metalloproteins is improved; a method suitable for separating the metalloproteome from the tissue or cell under the excess heavy metal treatment condition is established.

The invention discloses a matrix metalloproteinase gene (mmp) derived from a Lepidoptera pest, whic has the nucleotide sequence shown in SEQ ID NO: 1. The invention also discloses a protein encoded by the gene mmp, which has an amoni acid sequence shown in SEQ ID NO: 2. The invention further discloses the use of the gene mmp in regulation of allergic reaction of Lepidoptera pests.

This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of MMP13 genes.